{
    "clinical_study": {
        "@rank": "164695", 
        "arm_group": [
            {
                "arm_group_label": "Phase 1b and Phase 2 Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Talimogene laherparepvec plus ipilimumab"
            }, 
            {
                "arm_group_label": "Phase 2 Arm 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Ipilimumab"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase 1b of the study will evaluate the safety of talimogene laherparepvec in combination\n      with ipilimumab.  Phase 2 is a randomized study that will evaluate the safety and efficacy\n      of talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone.\n      Talimogene laherparepvec will be administered by intratumor injection, and ipilimumab will\n      be administered by intravenous infusion for a total of 4 infusions.  Subjects will be\n      treated with talimogene laherparepvec until complete response, all injectable tumors have\n      disappeared, disease progression per a modified Immune-Related Response Criteria (irRC), or\n      intolerance of study treatment."
        }, 
        "brief_title": "Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed diagnosis of malignant melanoma.\n\n          -  Stage IIIb, IIIc, IVM1a, IVM1b, or IVM1c disease that is not suitable for surgical\n             resection\n\n          -  Treatment na\u00efve: Must not have received any prior systemic anticancer treatment\n             consisting of chemotherapy, immunotherapy, or targeted therapy for unresected stage\n             IIIb to IV melanoma.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n          -  Adequate hematologic, hepatic, renal, and coagulation functions\n\n        Exclusion Criteria:\n\n          -  Primary uveal or mucosal melanoma\n\n          -  History or evidence of melanoma associated with immunodeficiency states (eg,\n             hereditary immune deficiency, organ transplant, or leukemia)\n\n          -  History or evidence of central nervous system (CNS) metastases\n\n          -  History or evidence of gastrointestinal inflammatory bowel disease (ulcerative\n             colitis or Crohn disease) or other symptomatic autoimmune disease\n\n          -  History of or plan for splenectomy or splenic irradiation\n\n          -  Active herpetic skin lesions or prior complications of HSV-1 infection (eg, herpetic\n             keratitis or encephalitis).\n\n          -  Requires intermittent or chronic systemic (intravenous or oral) treatment with an\n             antiherpetic drug (eg, acyclovir), other than intermittent topical use\n\n          -  Known human immunodeficiency virus (HIV) disease\n\n          -  Known acute or chronic hepatitis B or hepatitis C infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "149", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740297", 
            "org_study_id": "20110264"
        }, 
        "intervention": [
            {
                "arm_group_label": "Phase 1b and Phase 2 Arm 1", 
                "description": "Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter. Ipilimumab administered intravenously on Day 1 of Week 6, Week 9, Week 12, and Week 15 for a total of 4 infusions. Subjects will be treated wtih talimogene laherparepvec until complete response, all injectable tumors have disappeared, disease progression per the modified irRC, or intolerance of study treatment, whichever occurs first.", 
                "intervention_name": "Talimogene laherparepvec plus ipilimumab", 
                "intervention_type": "Drug", 
                "other_name": "Talimogene laherparepvec plus Yervoy"
            }, 
            {
                "arm_group_label": "Phase 2 Arm 2", 
                "description": "Ipilimumab administered intravenously on Day 1 of Week 1, 4, 7, and 10 for a total of 4 infusions.", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Drug", 
                "other_name": "Yervoy"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "melanoma, talimogene laherparepvec, ipilimumab, metastatic melanoma, melanoma, immunotherapy, unresectable melanoma, oncolytic immunotherapy,", 
        "lastchanged_date": "May 21, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90025"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Rosa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95403"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32207"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lakeland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33805"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46260"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Canton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44718"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresected, Stage IIIb-IV Melanoma", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Phase 1b: Determine the safety and tolerability of talimogene laherparepvec in combination with ipilimumab as assessed by incidence of dose-limiting toxicities (DLT)", 
                "measure": "Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks following last subject enrolled"
            }, 
            {
                "description": "Phase 2: Estimate the efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone as assessed by overall survival (OS)", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "24 months following last subject randomized"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740297"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Phase 1b: Objective Response Rate (ORR)", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "24 months following last subject enrolled"
            }, 
            {
                "description": "Phase 1b and Phase 2: Incidence of all AEs, grade 3 or greater AEs, Serious adverse events, events requiring discontinuation of study drug, local effects on tumor, clinically significant laboratory changes, and clinically significant changes in vital signs", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "24 months following last subject enrolled"
            }, 
            {
                "description": "Phase 2: Objective Response Rate, Time to Response (TTR), Duration of Response (DOR), Progression free survival (PFS), resection rate, 1-year survival rate, 2-year survival rate", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "24 months following last subject randomized"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}